Invited commentary: Hormone therapy and risk of coronary heart disease - Why renew the focus on the early years of menopause?

American Journal of Epidemiology

Volumn 166, Issue 5, 2007, Pages 511-517

  Manson, JoAnn E ^a,b   Bassuk, Shari S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Coronary disease; Estrogens; Hormone replacement therapy; Menopause; Observational studies; Progestins; Randomized controlled trials

Indexed keywords

CALCIUM; ESTROGEN; GESTAGEN; PLACEBO;

CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE TREATMENT; HEALTH RISK; HORMONE; SYMPTOM; WOMENS HEALTH;

ADRENERGIC SYSTEM; ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE COURSE; EARLY MENOPAUSE; HORMONAL THERAPY; HUMAN; HYPOTHESIS; ISCHEMIC HEART DISEASE; MONOTHERAPY; PREVENTIVE MEDICINE; REVIEW; SHORT COURSE THERAPY; SYMPTOM; VASOMOTOR DISORDER;

AGED; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEART DISEASES; HUMANS; MENOPAUSE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS;

EID: 34548043257     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm213     Document Type: Review

References (37)

1. Grodstein F, Stampfer M. The epidemiology of postmenopausal hormone therapy and cardiovascular disease. In: Goldhaber SZ, Ridker PM, eds. Thrombosis and thromboembolism. New York, NY: Marcel Dekker, 2002:67-78.
2. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
4. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
5. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
6. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65.
7. Writing Group for theWomen's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
8. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
9. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.
10. Michels KB, Manson JE. Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003;107:1830-3.
11. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7.
12. Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006;13:139-47.
13. Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54.
14. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-19.
15. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
16. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
17. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
18. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8.
19. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
20. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 2007;166:506-10.
21. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
22. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
23. Brownley KA, Hinderliter AL, West SG, et al. Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 2004;190:1052-8.
24. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004;164:482-4.
25. Salpeter SR,Walsh JM, Greyber E, et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-6.
26. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
27. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804.
28. Hecht HS, Budoff MJ, Berman DS, et al. Coronary artery calcium scanning: clinical paradigms for cardiac risk assessment and treatment. Am Heart J 2006;151:1139-46.
29. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary artery calcification. N Engl J Med 2007;356:2591-602.
30. ELITE: Early versus Late Intervention Trial with Estradiol. Bethesda, MD: National Institute on Aging, 2007. (http://clinicaltrials.gov/ct/show/ NCT00114517?order1/41). Accessed June 15, 2007.
31. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.
32. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005;142:855-60.
33. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Executive summary. Hormone therapy. Obstet Gynecol 2004;104(suppl):1S-4S.
34. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-501.
35. Wathen CN, Feig DS, Feightner JW, et al. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004;170:1535-7.
36. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168-82.
37. Manson JE, Bassuk SS. Hot flashes, hormones & your health. New York, NY: McGraw-Hill, 2007.